A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination with Androgen Receptor Pathway Inhibitors in Subjects with Metastatic Prostate Cancer
| Protocol No. | CTO-ARX517-2011 | Scope | National |
|---|---|---|---|
| Principal Investigator | Nabil Adra | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I |
